Categories: BrainDiagnosticsNews

Nexstim Plc’s Financial Information in 2023

Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET)

Nexstim Plc’s Financial Information in 2023

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it will publish the following financial information in 2023:

The 2022 Financial Statements Release and Half-Yearly Report July−December 2022 (H2) on Monday, February 27, 2023. Half-Yearly Report January-June 2023 (H1) on Friday, August 11, 2023.

Nexstim’s Annual Report 2022 will be published and available on the Company’s website on Monday, March 6, 2023.

The Annual General Meeting is tentatively scheduled to be held on Friday March 31, 2023 at 10:00 am.

NEXSTIM PLC        

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

Staff

Recent Posts

Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed

GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in…

8 hours ago

Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase

This app will connect people with strangers to meditate together in the real world—an invitation…

8 hours ago

IMG Saxony-Anhalt: 2026 in Sight – Saxony-Anhalt Sets the Pace for Future Industries

Despite challenging framework conditions such as high energy prices, the international introduction of tariffs, and…

8 hours ago

Kirby Medical Center Partners with Switchboard, MD to Automate Patient Communication Workflows

ATLANTA, Dec. 19, 2025 /PRNewswire/ -- Switchboard, MD is proud to announce a new enterprise partnership with…

8 hours ago

SIERRA7 RECOGNIZED AS A 2026 ELEV8 GOVCON AWARD WINNER

MCLEAN, Va., Dec. 19, 2025 /PRNewswire/ -- Sierra7, a leader in government healthcare and technology solutions,…

8 hours ago

Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Medome is the first AI technology for Personal Health…

8 hours ago